Komal Jhaveri: OS Benefit with Adjuvant Abemaciclib in High-Risk Breast Cancer
Aug 30, 2025, 18:08

Komal Jhaveri: OS Benefit with Adjuvant Abemaciclib in High-Risk Breast Cancer

Komal Jhaveri, Medical Oncologist and Clinical Researcher of Breast Medicine and Early Drug Development S, Section Head of Endocrine Therapy, Breast Medicine Service, and Clinical Director of Early Drug Development Service at Memorial Sloan Kettering Cancer Center, shared a post on X:

“Fantastic news for patients! OS benefit with adjuvant abemaciclib for 2 years for high-risk node-positive patients. Congratulations to everyone involved with the monarchE trial. Awaiting details at an upcoming meeting.”

Naoto T Ueno, Director of the University of Hawai’i Cancer Center, shared this post, adding:

“A significant milestone to show the OS improvement. The next step is to review the magnitude, toxicity, and cost to define the impact on long-term care. It is still 300K per treatment, and many people drop out.”

Read further.

More posts featuring Komal Jhaveri and Naoto T Ueno.